Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.65 |
| ▸ | NQO2 | P16083 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794641 | 1.00 | PPARG (0.65) | PPARGNQO2MAPTLMNAMMP13 | |
| SCHEMBL12632941 | 0.90 | PPARG (0.57) | PPARGMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL3793581 | 0.89 | PPARG (0.64) | PPARGNQO2MAPTLMNAMMP13 | |
| SCHEMBL3793587 | 0.89 | PPARG (0.64) | PPARGNQO2MAPTLMNAMMP13 | |
| SCHEMBL13372018 | 0.89 | PPARG (0.64) | PPARGNQO2MAPTLMNAMMP13 | |
| SCHEMBL4654616 | 0.85 | PPARG (0.60) | PPARGNQO2MAPTLMNAFFAR1 | |
| SCHEMBL4654618 | 0.85 | PPARG (0.60) | PPARGNQO2MAPTLMNAFFAR1 | |
| SCHEMBL14087880 | 0.85 | PPARG (0.60) | PPARGNQO2MAPTLMNAFFAR1 | |
| SCHEMBL3797579 | 0.85 | PPARG (0.59) | PPARGNQO2MAPTLMNAMEN1 | |
| SCHEMBL3793593 | 0.85 | PPARG (0.59) | PPARGNQO2MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718682-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7407978-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7323496-B2 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323496-B2 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323496-B2 | Compounds for treatment of inflammation, diabetes and related disorders | THERACOS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | NEOGI PARTHA | 2007-11-08 | — | — | US | disclosed |
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | NEOGI PARTHA | 2007-11-08 | — | — | US | disclosed |
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | NEOGI PARTHA | 2007-11-08 | — | — | US | disclosed |
| US-20040097593-A1 | Compounds for treatment of inflammation, diabetes and related disorders | SEED, BRIAN | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259961-A9 | COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS | CPS1, ABAT, IL6 | PPARG 106/4885NQO2 2306/4885MAPT 3945/4885 |
| US-20080103302-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | PPARG 99/4885NQO2 2286/4885MAPT 3929/4885 |
| US-20080108825-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | PPARG 99/4885NQO2 2286/4885MAPT 3929/4885 |
| US-20040097593-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | PPARG 106/4885NQO2 2306/4885MAPT 3945/4885 |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | PPARG 10/4885NQO2 1897/4885MAPT 4326/4885 |
| US-20080188654-A1 | Compounds for treatment of inflammation, diabetes and related disorders | CPS1, ABAT, IL6 | PPARG 99/4885NQO2 2286/4885MAPT 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.